Phase 1 Clinical Study of MWN109 Injection in Healthy Chinese Volunteers

1. Male or female participants aged 18 to 45 years (inclusive) at the time of signing the informed consent form (ICF); the proportion of either gender shall not be less than 1/3.

2. Male participants with body weight not less than 50 kg, female participants with body weight not less than 45 kg; body mass index (BMI) within 19.0 to 28.0 kg/m^2 (inclusive).

3. From the time of signing the informed consent form (ICF) until 3 months after the last dose, participants must have no plans to become pregnant or to father a child, must agree to use effective contraceptive measures to prevent pregnancy or causing a partner to become pregnant, and must have no plans to donate sperm or eggs.

1. History of severe drug allergy (especially known or suspected allergy to the excipients of MWN109 Injection) or severe atopic allergic diseases/history (asthma, urticaria, eczematous dermatitis, etc.) or severe allergic constitution (allergy to two or more foods or drugs) (by inquiry).

2. History of acute or chronic pancreatitis, symptomatic gallbladder disease, pancreatic injury or other high-risk factors that may lead to pancreatitis, or serum amylase > 1.5 × upper limit of normal (ULN) at screening (by inquiry and examination).

3. Family history or history of medullary thyroid C-cell tumor/carcinoma; history of thyroid dysfunction or abnormal thyroid hormone levels (by inquiry).

4. History or presence at screening of digestive system diseases that may increase the risk to volunteers, such as pancreatitis, abnormal gastric emptying (e.g., gastroparesis, pyloric stenosis, pyloric obstruction, etc.), or severe chronic gastrointestinal diseases (e.g., history of intestinal obstruction, active ulcer within 6 months) (by inquiry).

5. History of infectious diseases (which, in the investigator's assessment, may significantly affect the safety evaluation of volunteers) or severe trauma within 4 weeks before screening, or major surgery within 3 months before screening (by inquiry and examination).

6. Use of any prescription or over-the-counter drug (including chemical drugs, vitamins, herbal medicines, etc.) within 2 weeks before dosing (by inquiry and examination);

7. History of substance abuse (by inquiry).

8. Blood donation or massive blood loss (> 400 mL) or blood transfusion within 3 months before screening (by inquiry).